Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635185 | 0.90 | KCNH2 (0.66) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4635181 | 0.84 | KCNH2 (0.58) | KCNH2CYP11B1CYP11B2SMN1; SMN2LMNA | |
| SCHEMBL4635198 | 0.84 | KCNH2 (0.58) | KCNH2CYP11B1CYP11B2SMN1; SMN2LMNA | |
| SCHEMBL4634238 | 0.80 | KCNH2 (0.62) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4635971 | 0.80 | KCNH2 (0.62) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL509350 | 0.79 | KCNH2 (0.61) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL5226016 | 0.78 | KCNH2 (0.54) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL2717764 | 0.77 | KCNH2 (1.00) | KCNH2CYP11B1CYP11B2SMN1; SMN2PRMT5 | |
| SCHEMBL509289 | 0.77 | KCNH2 (0.65) | KCNH2CYP11B1CYP11B2SMN1; SMN2LMNA | |
| SCHEMBL509689 | 0.77 | KCNH2 (0.79) | KCNH2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556359-B1 | PYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS FOR HIV MEDIATED DISEASES | PFIZER LTD (GB) | 2008-06-18 | — | — | EP | disclosed |
| EP-1556359-B1 | PYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS FOR HIV MEDIATED DISEASES | PFIZER LTD (GB) | 2008-06-18 | — | — | EP | disclosed |
| US-7220772-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220772-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20050054707-A1 | Pyrazole derivatives | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054707-A1 | Pyrazole derivatives | RTF1, PDCD11, RRM2B | KCNH2 3264/4885CYP11B1 524/4885CYP11B2 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.